RT Journal Article
T1 No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
A1 Castaño-Bonilla, Tamara
A1 Barragán, Eva
A1 Sargas, Claudia
A1 Sanz, Alejandro
A1 Algarra, Lorenzo
A1 Herrera-Puente, Pilar
A1 García-Boyero, Raimundo
A1 Barrios, Manuel
A1 Martinez-Cuadron, David
A1 Rodriguez-Veiga, Rebeca
A1 Boluda, Blanca
A1 Gil, Cristina
A1 Serrano-López, Josefina
A1 Martínez-López, Joaquín
A1 Sayas-Lloris, María José
A1 Olave, María Teresa
A1 Riaza-Grau, Rosalía
A1 Castillo, Teresa Bernal-Del
A1 Larrayoz, María José
A1 Amigo, Raquel
A1 Jiménez-Velasco, Antonio
A1 Sánchez, Joaquín
A1 Ayala, Rosa
A1 Blas, Carlos
A1 Lainez, Daniel
A1 Serrano-López, Juana
A1 Sanz, Miguel A
A1 Alonso-Domínguez, Juan M
A1 Montesinos, Pau
AB Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO to intensive treatment in contrast to patients with CT/TT genotypes. Nevertheless, contradictory results have been reported. We sought to shed light on the prediction of GO response in AML patients with rs12459419 polymorphism who were treated with GO in the consolidation (n = 70) or reinduction (n = 20) phase. The frequency distribution of the rs12459419 polymorphism in the complete cohort of patients was 44.4% (n = 40), 50% (n = 45), and 5.6% (n = 5) for CC, CT, and TT genotypes, respectively. Regarding the patients treated with GO for consolidation, we performed a Kaplan-Meier analysis of overall survival and relapse-free survival according to the rs12459419 polymorphism (CC vs. CT/TT patients) and genetic risk using the European Leukemia Net (ELN) 2010 risk score. We also carried out a Cox regression analysis for the prediction of overall survival, with age and ELN 2010 as covariates. We found no statistical significance in the univariate or multivariate analysis. Additionally, we performed a global Kaplan-Meier analysis for the patients treated with GO for reinduction and did not find significant differences; however, our cohort was too small to draw any conclusion from this analysis. The use of GO in consolidation treatment is included in the approval of the compound; however, evidence regarding its efficacy in this setting is lacking. Rs12459419 polymorphism could help in the selection of patients who might benefit from GO. Regrettably, in our cohort, the rs12459419 polymorphism does not seem to be an adequate tool for the selection of patients who might benefit from the addition of GO in consolidation cycles.
YR 2022
FD 2022-08-23
LK http://hdl.handle.net/10668/20173
UL http://hdl.handle.net/10668/20173
LA en
DS RISalud
RD Apr 10, 2025